GSK’s Vaccine Sales Plummet in Q3, Highlighting Reduced Demand and Market Challenges

Vaccine Sales Decline:
GSK experienced a significant decline in vaccine sales in the third quarter, particularly with its respiratory syncytial virus (RSV) vaccine Arexvy, which saw a 72% drop in sales.

Shingrix Performance:
The company's shingles vaccine, Shingrix, also faced challenges, with quarterly sales dropping 10% to £739 million.

Influenza Vaccine Sales:
Sales of GSK's influenza vaccine slumped 24% in the third quarter, contributing to the overall decline in vaccine sales.

Reduced Demand:
The decline in vaccine sales is attributed to reduced demand, leading GSK to cut its vaccine sales target.

Impact on Overall Sales:
The slump in vaccine sales hampered GSK's overall sales growth in the third quarter.